Best of ASCO - 2014 Annual Meeting



Attend this session at the
2019 ASCO Annual Meeting!

Session: Gastrointestinal (Noncolorectal) Cancer

Type: Oral Abstract Session

Time: Sunday June 2, 9:45 AM to 12:45 PM

Location: Arie Crown Theater

Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.

Esophageal or Gastric Cancer

Gastrointestinal (Noncolorectal) Cancer

2019 ASCO Annual Meeting

Abstract No:

J Clin Oncol 37, 2019 (suppl; abstr 4006)

Author(s): Peter S Hall, Daniel Swinson, Justin S. Waters, Jonathan Wadsley, Stephen Falk, Rajarshi Roy, Tania Tillett, Jonathan Nicoll, Sebastian Cummings, Simon Aird Grumett, Konstantinos Kamposioras, Angel Garcia, Christine Allmark, Helen Marshall, Sharon Ruddock, Eszter Katona, Galina Velikova, Russell D. Petty, Heike I. Grabsch, Matthew T. Seymour; University of Edinburgh, Edinburgh, United Kingdom; St James, Leeds, United Kingdom; Kent Oncology Centre, Maidstone, United Kingdom; Weston Park Hospital, Sheffield, United Kingdom; Bristol Haematology and Oncology Centre, Bristol, United Kingdom; Castle Hill Hospital, Hull, United Kingdom; Royal United Hospital, Bath, Bath, United Kingdom; North Cumbria University Hospitals, Carlisle, United Kingdom; Royal Surrey County Hospital, Guildford, United Kingdom; Royal Wolverhampton Hospitals, Wolverhampton, United Kingdom; Mid-Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom; Betsi Cadwaladr LHB, Bangor, United Kingdom; NCRI Consumer Forum, London, United Kingdom; CTRU, Leeds, United Kingdom; CTRU, University of Leeds, Leeds, United Kingdom; University of Leeds, Leeds, United Kingdom; University of Aberdeen, Aberdeen, Scotland; Leeds Institute of Cancer Studies and Pathology, University of Leeds, Leeds, United Kingdom; National Institute for Health Research Clinical Research Network, Leeds, United Kingdom

Abstract Disclosures


Background: Many pts with aGOAC are elderly and/or frail. We previously compared epirubin/ oxaliplatin/ capecitabine (EOCap) vs OCap vs Cap in a pick-the-winner study and found OCap best. GO2 was designed to find the optimum dose of OCap and to explore the use of an objective baseline geriatric assessment to individualize doses for maximum Overall Treatment Utility (OTU), a composite of clinical benefit, tolerability, QL and patient value. Methods: Pts with aGOAC were eligible if unsuitable for full-dose EOCap due to age or frailty, but fit for OCap; GFR ≥ 30, bili <2x ULN. Baseline assessment included global QL; symptoms; functional scales; comorbidity; frailty. Randomization was 1:1:1 to dose Level A (Ox 130 mg/m2d1, Cap 625 mg/m2bd d1-21, q21d), B (80% Level A doses) or C (60% Level A doses). Pts with GFR 30-50 ml/min or bili 1.5-2.0 xULN received 75% of the allocated dose of Cap. At 9 wks, pts were scored for OTU. Continuation thereafter was based on clinical judgement. Non-inferiority (vs A) was assessed using PFS censored at 12 months, with boundary HR 1.34 (based on discussion with pts and clinicians), needing 284 PFS events per 2-way comparison. Baseline fitness was assessed as predictive of OTU, overall and by interaction with dose level. Results: 514 pts were randomised, 2014-17, at 61 UK centres. Clinical trial information: 44687907. Non-inferiority of PFS is confirmed for Level B vs A (HR 1.09, CI 0.89-1.32) and for Level C vs A (HR 1.10, CI 0.90-1.33). Level C pts had less toxicity and better OTU outcomes than A or B. When analysed by baseline age, frailty and PS, Level C produced the best OTU even in younger, less frail and better PS patients; no group was identified who benefit more from the higher dose levels. Conclusions: This is the largest RCT to date specifically investigating frail and/or elderly aGOAC pts, and should guide future treatment. The lowest dose tested was non-inferior in terms of PFS and produced less toxicity and better overall treatment utility.

Level ALevel BLevel C
Pts (PFS events)170 (142).171 (147).173 (149)
Median age767677
% PS ≥2313231
% any Frailty; % very Frail86; 6182; 5676; 58
% any Gr ≥3 non-haem adverse event.565637
Median PFS mo4.94.14.3
OTU (wk 9): % Good/intermed./poor35/34/3136/26/3843/27/29
Median OS mo7.56.77.6

Other Abstracts in this Sub-Category:


1. ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 4001 First Author: Se Hoon Park
Category: Gastrointestinal (Noncolorectal) Cancer - Esophageal or Gastric Cancer


2. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

Meeting: 2019 ASCO Annual Meeting Abstract No: LBA4007 First Author: Josep Tabernero
Category: Gastrointestinal (Noncolorectal) Cancer - Esophageal or Gastric Cancer


3. Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.

Meeting: 2019 ASCO Annual Meeting Abstract No: 4009 First Author: Zev A. Wainberg
Category: Gastrointestinal (Noncolorectal) Cancer - Esophageal or Gastric Cancer